ESCC Clinical Trial
Official title:
Safety and Efficacy of Tislelizumab Combined With Chemoradiotherapy in First-line Treatment of Stage IVb Esophageal Squamous Cell Carcinoma
This study is a single-arm, prospective, open-label clinical study to evaluate the safety and efficacy of tislelizumab combined with chemoradiotherapy in first-line treatment of patients with stage IVb esophageal squamous cell carcinoma.
This study is a single-center, prospective, single-arm, open-label study. It will explore the efficacy and safety of tislelizumab combined with nab-paclitaxel in the first-line treatment of stage IVb esophageal squamous cell carcinoma on the basis of low-dose radiotherapy（40Gy/20f，5次/w）. To explore new treatment modalities and prolong patient survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05050760 -
DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
|
N/A | |
| Not yet recruiting |
NCT04471480 -
TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer
|
N/A | |
| Recruiting |
NCT04686682 -
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04863079 -
Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )
|
Phase 2 | |
| Completed |
NCT04939701 -
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
|
Phase 1/Phase 2 |